Price T Rowe Associates Inc Verona Pharma PLC Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Verona Pharma PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 949,375 shares of VRNA stock, worth $27.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
949,375Holding current value
$27.7 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
137Shares Held
66.7MCall Options Held
495KPut Options Held
486K-
Ra Capital Management, L.P. Boston, MA7.63MShares$223 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$163 Million7.62% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$117 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$104 Million7.58% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.31MShares$96.7 Million2.82% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $1.78B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...